Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.74 | — | — | — | — | 41.45 | — | — | — | — | — | 3.20 | 0.98 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.62 | 7.30 | 3.60 | 2.44 | 5.45 | 4.05 | 3.57 | 6.96 | 8.37 | 3.91 | 18.11 | 2.03 | 0.72 |
| — | +80.5% | +0.8% | -64.9% | -34.8% | +3.4% | -80.3% | +243.5% | +1068.4% | -46.6% | +371.8% | -94.0% | -98.3% | |
| P/B Ratio | 0.92 | 2.23 | 1.53 | 1.23 | 1.90 | 2.40 | 2.54 | 3.44 | 3.01 | 2.42 | 2.67 | 1.98 | 1.70 |
| — | -7.0% | -39.8% | -64.3% | -36.9% | -1.1% | -4.9% | +74.0% | +77.4% | -10.0% | +9.6% | -48.6% | -60.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 3.77 | — | 0.73 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 5.80 | 0.33 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | 6.03 | 0.33 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Arcturus Therapeutics Holdings Inc.'s operating margin was -96.3% in Q3 2025, down 48.9 pp QoQ and down 68.6 pp YoY. The trailing four-quarter average of -90.0% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 19.5% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 80.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 64.4% | 35.5% | 83.2% |
| — | -19.5% | 0.0% | 0.0% | 0.0% | 0.0% | +55.2% | +181.5% | +20.2% | +155.0% | +257.3% | +104.7% | +119.3% | |
| Operating Margin | -69.1% | -96.3% | -47.4% | -57.3% | -159.0% | -27.7% | -46.0% | -93.3% | -72.9% | -44.5% | -526.4% | 18.4% | 75.8% |
| — | -248.0% | -3.1% | +38.6% | -118.3% | +37.9% | +91.3% | -607.6% | -196.2% | +83.8% | -545.7% | +101.9% | +111.7% | |
| Net Margin | -58.5% | -78.4% | -37.5% | -47.9% | -142.9% | -17.8% | -37.4% | -82.3% | -46.7% | -37.4% | -499.6% | 63.2% | 73.2% |
| — | -340.9% | -0.0% | +41.8% | -206.1% | +52.4% | +92.5% | -230.1% | -163.8% | +85.8% | -527.7% | +106.5% | +111.0% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -31.2% | -5.9% | -4.0% | -5.9% | -11.9% | -2.7% | -6.6% | -9.9% | -4.2% | -5.7% | -17.1% | 16.9% | 56.4% |
| — | -122.5% | +40.1% | +40.0% | -184.7% | +53.8% | +61.5% | -158.4% | -107.4% | +74.3% | -41.0% | +168.3% | +455.6% | |
| ROA | -20.9% | -4.5% | -2.9% | -4.2% | -8.4% | -1.8% | -4.3% | -6.3% | -2.6% | -3.7% | -11.7% | 11.0% | 31.5% |
| — | -150.0% | +32.8% | +34.1% | -218.1% | +50.2% | +63.4% | -157.4% | -108.4% | +67.3% | -83.6% | +179.1% | +437.5% | |
| ROIC | -291.5% | -19.4% | -14.4% | -27.4% | -57.8% | -57.0% | — | -188.3% | -76.0% | -218.3% | -292.5% | 288.5% | — |
| — | +66.0% | — | +85.4% | +23.9% | +73.9% | — | -165.3% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 65.1% YoY to 7.86x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.10 | 0.12 | 0.18 | 0.12 | 0.11 | 0.12 | 0.12 | 0.11 | 0.18 | 0.11 | 0.10 | 0.35 |
| — | -13.3% | -2.3% | +50.9% | +9.2% | -38.6% | +5.8% | +20.0% | -69.1% | -71.9% | -80.4% | -73.1% | +15.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 2.16 | 0.78 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.67 | 7.86 | 5.90 | 5.64 | 4.67 | 4.76 | 3.78 | 3.26 | 4.72 | 4.49 | 4.26 | 4.71 | 3.18 |
| — | +65.1% | +56.0% | +73.3% | -0.9% | +6.2% | -11.3% | -30.9% | +48.5% | +37.9% | +35.7% | +54.6% | -16.6% | |
| Quick Ratio | 4.67 | 7.86 | 5.90 | 5.64 | 4.67 | 4.76 | 3.78 | 3.26 | 4.72 | 4.49 | 4.26 | 4.71 | 3.18 |
| — | +65.1% | +56.0% | +73.3% | -0.9% | +6.2% | -11.3% | -30.9% | +48.5% | +37.9% | +35.7% | +54.6% | -16.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | -4568.00 | -965.70 | — | 19.86 | 153.74 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonArcturus Therapeutics Holdings Inc.'s current P/E is -2.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Arcturus Therapeutics Holdings Inc.'s current operating margin is -69.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Arcturus Therapeutics Holdings Inc.'s business trajectory between earnings reports.